In this issue:
ASCT is a valuable consolidation therapy in selected elderly patients
IVIg and longer dosing intervals reduce risk of teclistamab-related infections
ICON: All-oral IberCd promising for lenalidomide-refractory RRMM
Analysis of temporal changes in SMM reveals improved prognosis
SMM may be a heterogenous clinical stage bridging MGUS and MM
Cilta-cel prolongs survival in lenalidomide-refractory RRMM
Talquetamab + teclistamab combo efficacious for extramedullary disease
Belantamab mafodotin does not induce BCMA loss or systemic immune dysfunction
CTCs are a compound biomarker for high-risk genomic alterations and tumour load
Anti-GPRC5D CAR T-cell therapy promising for post BCMA-directed therapy relapse
Please login below to download this issue (PDF)